ANI Pharmaceuticals Company Profile (NASDAQ:BPAX)

About ANI Pharmaceuticals (NASDAQ:BPAX)

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BPAX
  • CUSIP: N/A
  • Web: www.anipharmaceuticals.com
P/E:
  • Trailing P/E Ratio:
  • Foreward P/E Ratio: -1.28
  • P/E Growth:
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 5.99%
  • Return on Equity: 6.12%
  • Return on Assets: 3.00%
 

Frequently Asked Questions for ANI Pharmaceuticals (NASDAQ:BPAX)

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "BPAX."

Who are some of ANI Pharmaceuticals' key competitors?

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the folowing people:

  • Robert E. Brown Jr., Independent Chairman of the Board
  • Arthur S. Przybyl, President, Chief Executive Officer, Director
  • Stephen P. Carey, Chief Financial Officer, Vice President
  • James G. Marken, Vice President - Operations
  • Mark J. Ginski Ph.D., Vice President of Corticotropin Product Development
  • Karen Quinn Ph.D., Vice President - Corticotropin Regulatory Affairs
  • Robert W. Schrepfer, Vice President - New Business Development and Contract Manufacturing
  • Fred E. Holubow, Independent Director
  • Tracy L. Marshbanks Ph.D., Independent Director
  • Thomas A. Penn, Independent Director

How do I buy ANI Pharmaceuticals stock?

Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANI Pharmaceuticals stock can currently be purchased for approximately $1.09.


MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ BPAX)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ANI Pharmaceuticals (NASDAQ:BPAX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:BPAX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/26/2015Roth CapitalBoost Price Target$1.00 -> $3.00N/AView Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for ANI Pharmaceuticals (NASDAQ:BPAX)
Earnings by Quarter for ANI Pharmaceuticals (NASDAQ:BPAX)
Earnings History by Quarter for ANI Pharmaceuticals (NASDAQ BPAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2012Q312($0.36)($0.27)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ANI Pharmaceuticals (NASDAQ:BPAX)
Current Year EPS Consensus Estimate: $-1.50 EPS
Next Year EPS Consensus Estimate: $-0.85 EPS

Dividends

Dividend History for ANI Pharmaceuticals (NASDAQ:BPAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ANI Pharmaceuticals (NASDAQ:BPAX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for ANI Pharmaceuticals (NASDAQ:BPAX)
Latest Headlines for ANI Pharmaceuticals (NASDAQ:BPAX)
Source:
DateHeadline
americanbankingnews.com logoCritical Comparison: Concert Pharmaceuticals (CNCE) & ANI Pharmaceuticals (BPAX)
www.americanbankingnews.com - August 17 at 4:22 PM
americanbankingnews.com logoANI Pharmaceuticals Inc (ANIP) Earns “Neutral” Rating from Guggenheim
www.americanbankingnews.com - March 9 at 9:00 AM

Social

Chart

ANI Pharmaceuticals (BPAX) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff